BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
Biopharmaceutical company InnoCare Pharma Ltd. (9969.HK; 688428.SH) announcedon Monday that it, along with KeyMed (2162.HK) and their joint venture have signed a licensing deal for one of their products with…
FAST NEWS: InnoCare inches closer to profitability on strong sales gains
The latest: InnoCare Pharma Ltd. (9969.HK) announced Tuesday its first-quarter revenue jumped 59% year-over-year to 189 million yuan ($27.3 million), while its net loss narrowed 90% to 12.41 million yuan. Looking…
Henlius Swallows Bitter Pill in Watered-Down Licensing Deal
The innovative drug company will receive less benefits from an existing licensing deal after revisions to reflect high R&D costs Key Takeaways: Henlius Biotech will receive up to $11 million…
FAST NEWS: InnoCare Pharma’s Loss Soars on R&D Costs, Exchange Losses
The latest: InnoCare Pharma Ltd. (9969.HK) said it expects to report its net loss soared about 13 times to 910 million yuan ($134 million) last year, according to a profit…
Losses Mount at InnoCare but Cash Cushion Dulls the Pain
The cancer drug developer logged another loss in the latest quarter but a cash pile of more than 9.2 billion yuan can sustain its business for the next five yearsKey…
No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
InnoCare Revs Up for Next Phase With Strong Results, IPO Plan
Sales of the company’s key Orelabrutinib cancer drug doubled in the first half of the year, contributing to a 142% revenue jump for the period Key Takeaways: InnoCare Pharma’s revenue…
Recent Articles
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK -
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
-
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK 688428.SHG
-
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
- Waiting for new industry dawn, SolarSpace turns to IPO for warmth
